SCHEMBL365596

SCHEMBL365596

CC(C)(C(=O)O)c1ncccc1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.42
LMNA P02545 1/20 0.42
PKM P14618 1/20 0.39
DHODH Q02127 1/20 0.38
PTGFR P43088 3/20 0.38
HTT P42858 1/20 0.38
TRPV1 Q8NER1 2/20 0.38
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
KDM4E B2RXH2 3/20 0.36
TDP1 Q9NUW8 2/20 0.36
CYP3A4 P08684 1/20 0.36
ALOX12 P18054 1/20 0.36
DOT1L Q8TEK3 1/20 0.36
PABPC1 P11940 1/20 0.35
EIF4H Q15056 1/20 0.35
TRPA1 O75762 1/20 0.35
KCNH2 Q12809 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3869346 0.84 SMN1; SMN2 (0.43) SMN1; SMN2LMNAPKMHTTTRPV1
SCHEMBL30486616 0.80 POLB (0.42) SMN1; SMN2LMNAPKMHTTTRPV1
SCHEMBL10198453 0.80 POLB (0.42) SMN1; SMN2LMNAPKMHTTTRPV1
SCHEMBL131219 0.80 SSTR4 (0.46) SMN1; SMN2LMNAHTTTRPV1ALDH1A1
SCHEMBL21631946 0.79 SLC22A12 (0.38) SMN1; SMN2LMNAPKMDHODHPTGFR
SCHEMBL21631978 0.79 PTGFR (0.44) SMN1; SMN2LMNAPKMDHODHPTGFR
SCHEMBL131218 0.79 KDM4E (0.36) SMN1; SMN2LMNAALDH1A1KDM4ETDP1
SCHEMBL26622744 0.79 NAPRT (0.42) SMN1; SMN2LMNAHTTTRPV1ALDH1A1
SCHEMBL31254559 0.79 KDM4E (0.40) SMN1; SMN2LMNAALDH1A1KDM4ETDP1
SCHEMBL29700926 0.79 NAPRT (0.42) SMN1; SMN2LMNAHTTTRPV1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025072539-A1 AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF PLIANT THERAPEUTICS, INC. (US) 2025-04-03 WO disclosed
EP-3609869-A1 SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF Bayer Aktiengesellschaft (DE) 2020-02-19 EP disclosed
WO-2018189011-A1 SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2018-10-18 WO disclosed
EP-2593432-B1 N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS PFIZER LTD (GB) 2014-10-22 EP disclosed
US-8592629-B2 Sulfonamide derivatives as Nav 1.7 inhibitors PFIZER LIMITED (GB) 2013-11-26 US disclosed
EP-2593432-A1 N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS Pfizer Limited (GB) 2013-05-22 EP disclosed
WO-2012007861-A1 N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS PFIZER LIMITED (GB) 2012-01-19 WO disclosed
US-20120010183-A1 Chemical Compounds PFIZER LIMITED (GB) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010183-A1 Chemical Compounds SCN1A, SCN1B, SCN7A SMN1; SMN2 595/4885LMNA 2928/4885PKM 3956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.